(Q55122666)

21 June 2018

title

Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. (English)

1 reference

21 June 2018

1 reference

James J Hsieh

1

1 reference

21 June 2018

David Chen

2

1 reference

21 June 2018

Patricia I Wang

3

1 reference

21 June 2018

Mahtab Marker

4

1 reference

21 June 2018

Almedina Redzematovic

5

1 reference

21 June 2018

Ying-Bei Chen

6

1 reference

21 June 2018

S Duygu Selcuklu

7

1 reference

21 June 2018

Nils Weinhold

8

1 reference

21 June 2018

Nancy Bouvier

9

1 reference

21 June 2018

Kety H Huberman

10

1 reference

21 June 2018

Umesh Bhanot

11

1 reference

21 June 2018

Michael S Chevinsky

12

1 reference

21 June 2018

Parul Patel

13

1 reference

21 June 2018

Patrizia Pinciroli

14

1 reference

21 June 2018

Helen H Won

15

1 reference

21 June 2018

Daoqi You

16

1 reference

21 June 2018

Agnes Viale

17

1 reference

21 June 2018

William Lee

18

1 reference

21 June 2018

A Ari Hakimi

19

1 reference

21 June 2018

Michael F Berger

20

1 reference

21 June 2018

Nicholas D Socci

21

1 reference

21 June 2018

Emily H Cheng

22

1 reference

21 June 2018

Jennifer Knox

23

1 reference

21 June 2018

Martin H Voss

24

1 reference

21 June 2018

Maurizio Voi

25

1 reference

21 June 2018

Robert J Motzer

26

1 reference

21 June 2018

language of work or name

English

0 references

publication date

15 October 2016

1 reference

21 June 2018

published in

European Urology

1 reference

21 June 2018

volume

71

1 reference

21 June 2018

issue

3

1 reference

21 June 2018

page(s)

405-414

1 reference

21 June 2018

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

Therapeutic Guide for mTOuRing through the Braided Kidney Cancer Genomic River

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

A river model to map convergent cancer evolution and guide therapy in RCC.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

Kidney cancer, version 3.2015.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

Integrated molecular analysis of clear-cell renal cell carcinoma

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

Comprehensive molecular characterization of clear cell renal cell carcinoma

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

BAP1 loss defines a new class of renal cell carcinoma

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

mTOR inhibitors in advanced renal cell carcinoma

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

The genetic basis of kidney cancer: a metabolic disease

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431298

13 August 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/27751729

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27751729

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27751729

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.EURURO.2016.10.007

1 reference

21 June 2018

PMC publication ID

5431298

1 reference

21 June 2018

PubMed publication ID

27751729

1 reference

21 June 2018